title: [Adjuvant hormonal therapy immediately after radical surgery for high-risk organ-confined or locally advanced prostate cancer].
abstract: OBJECTIVE
  To evaluate the effect of adjuvant hormonal therapy (AHT) immediately after radical surgery for high- risk organ-confined or locally advanced prostate cancer using the PSA-related biochemical relapse rate within 2 years after surgery.
  
  
  METHODS
  We retrospectively analyzed 62 cases of high-risk organ-confined or locally advanced prostate cancer. The patients were treated by laparoscopic radical prostatectomy or radical retropubic prostatectomy after MRI and ECT systemic bone imaging examination, which revealed no regional lymph node or bone metastasis. Thirty-two of the patients (group A) received AHT orally or subcutaneously from 2 weeks to 1 months after operation, and another 30 (group B) were left untreated. We followed up the patients for 2 years, measuring the serum PSA level every 3 months, performing ECT every 6 months, and recording the adverse reactions, medication dura- tion, and the patients'quality of life.
  
  
  RESULTS
  All the operations were successfully accomplished. The rate of 2-year biochemical relapse-free survival was 78.13% (25/32) in group A and 53.33% (16/30) in group B.
  
  
  CONCLUSIONS
  AHT immediately after radical surgery can improve the rate of biochemical relapse-free survival of the patients with high-risk organ-confined or locally advanced prostate cancer and check the progression and metastasis of the disease.
authors.affiliation: Department of Urology, First Affiliated Hospital of Nanjing Medical University, Jiangsu, China.
authors.forename: Zhao-Long
authors.initials: ZL
authors.lastname: Guan
authors.forename: Liang
authors.initials: L
authors.lastname: Huang
authors.forename: Rui-Zhe
authors.initials: RZ
authors.lastname: Zhao
authors.forename: Gong
authors.initials: G
authors.lastname: Cheng
authors.forename: Chao
authors.initials: C
authors.lastname: Qin
authors.forename: Peng-Fei
authors.initials: PF
authors.lastname: Shao
authors.forename: Jie
authors.initials: J
authors.lastname: Li
authors.forename: Li-Xin
authors.initials: LX
authors.lastname: Hua
authors.forename: Chang-Jun
authors.initials: CJ
authors.lastname: Yin
mesh_terms: D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D018450:Disease Progression; D018572:Disease-Free Survival; D006801:Humans; D010535:Laparoscopy; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000097:blood; D009367:Neoplasm Staging; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy / Q000379:methods*; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D011788:Quality of Life; D012189:Retrospective Studies
chemical_list: D018931:Antineoplastic Agents, Hormonal; D017430:Prostate-Specific Antigen